Fig. 3

Waterfall plot of conteltinib (CT-707) in patients with ALK-positive NSCLC. Best percentage change from baseline in the sum of target lesions is presented for the ALK-positive evaluable patients (n=60). The dashed line at −30% indicates the threshold for PR and that at 20% for PD according to the Response Evaluation Criteria in Solid Tumors version 1.1. One patient achieved CR (dark green), 31 patients achieved PR (green), 18 patients attained SD (blue), and 10 patients experienced PD (pink). A–H represent patients who received conteltinib at the dose of 50 mg QD, 100 mg QD, 200 mg QD, 300 mg QD, 450 mg QD, 600 mg QD, 800 mg QD, and 300 mg BID, respectively; blue circles refer to patients who are ALK TKI-naïve, and red triangles are patients who received crizotinib previously (note: ^, two patients had unconfirmed response) ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; QD, quaque die; BID, bis in die; NSCLC, non-small cell lung cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease